Zynex, Inc. (ZYXI)
After hours:
| Previous close | 14.21 |
| Open | 14.09 |
| Bid | 13.51 x 1100 |
| Ask | 13.70 x 800 |
| Day's range | 13.28 - 14.69 |
| 52-week range | 4.97 - 17.25 |
| Volume | |
| Avg. volume | 217,147 |
| Market cap | 525.14M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | 29.02 |
| EPS (TTM) | 0.47 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Jan 2022 |
| 1y target est | 22.50 |
- PR Newswire
Zynex Monitoring Announces Community Blood Drive and Research Collaboration Trial for its Fluid Monitoring System
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today reported it will be hosting a blood donation drive on February 1, 2023 at its headquarters in Englewood, CO in partnership with Vitalant, the nation's largest independent, nonprofit blood services provider. The drive will fulfill an important and immediate need to help with the emergency sho
- PR Newswire
Zynex Recognized in The Power 500 Healthcare Technology Companies
Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex in The Power 500 Healthcare Technology Companies.
- PR Newswire
Zynex Reports Preliminary Fourth Quarter 2022 Results
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for fourth quarter 2022 and reiterated full year guidance.
